BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/21/2024 7:03:24 AM | Browse: 380 | Download: 1055
Publication Name World Journal of Hepatology
Manuscript ID 98142
Country China
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients
Manuscript Source Invited Manuscript
All Author List Wei-Hua Cao, Ya-Qin Zhang, Xin-Xin Li, Zi-Yu Zhang and Ming-Hui Li
ORCID
Author(s) ORCID Number
Ming-Hui Li http://orcid.org/0000-0003-3233-5473
Funding Agency and Grant Number
Funding Agency Grant Number
The National Key Research and Development Program 2022YFC2603500 and 2022YFC2603505
Beijing Municipal Health Commission High-Level Public Health Technical Personnel Construction Project Discipline leader-03-26
The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority XXZ0302
The Capital Health Research and Development of Special Public Health Project 2022-1-2172
Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support XMLX 202127
Corresponding Author Ming-Hui Li, MD, PhD, Chief Doctor, Professor, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Key Words Hepatitis B virus; Hepatocellular carcinoma; Immune checkpoint inhibitors; Peginterferon alpha; Systematic treatment
Core Tip Hepatitis B virus (HBV) infection interacts with tumor microenvironment (TME) through a highly complex and intertwined signaling pathway, which results in a special TME in hepatocellular carcinoma (HCC). Due to changes in the TME, tumor cells can evade immune surveillance by inhibiting tumor-specific T cell function through CTLA-4 and programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1). Interferon, as an immune factor with rich biological activity, can improve the TME of HBV-HCC through various pathways. Currently, the systematic treatment of HCC has gradually come out of the dilemma. In addition to the continuous emergence of new multi-target anti-vascular tyrosine kinase inhibitor drugs, immune checkpoint inhibitors have opened up a new situation for the systematic treatment of HCC, and the disease characteristics of patients included in global clinical studies are different from those of Chinese patients. Therefore, whether a group of HCC patients with HBV background and poor prognosis in China can also benefit from immunotherapy is a widely concerned issue.
Publish Date 2024-10-21 07:03
Citation

Cao WH, Zhang YQ, Li XX, Zhang ZY, Li MH. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World J Hepatol 2024; 16(10): 1158-1168

URL https://www.wjgnet.com/1948-5182/full/v16/i10/1158.htm
DOI https://dx.doi.org/10.4254/wjh.v16.i10.1158
Full Article (PDF) WJH-16-1158-with-cover.pdf